<DOC>
	<DOCNO>NCT02689947</DOCNO>
	<brief_summary>Prospective single center study evaluate safety effectiveness Restylane Silk treatment tear trough correction .</brief_summary>
	<brief_title>Evaluation Efficacy Restylane Silk Correction Tear Trough Deformity</brief_title>
	<detailed_description />
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>1 . Is healthy male female 21 65 year old 2 . Tear trough deformity , Hirmand Type1 Type2 3 . Is voluntarily willing consent participate study 4 . Is willing comply requirement study include photograph , follow post treatment care instruction , attend treatment , follow visit 5 . Willingness waive right use still photos research , marketing , promotional reason , include internet social medium outlet . 6 . Willingness refrain surgical , laser , injectable treatment periorbital region entire duration study . 7 . Ability provide inform consent . 1 . Marked delineation inferior orbital rim lateral aspect eyelid/orbit 2 . Use botulinum toxin periorbital region within past 6 month . 3 . Treatment injectable filler midface periorbital region within past 2 year treatment time past permanent filler midface periorbital region silicone , PMMA ( Artefill ) 4 . Laser skin resurface periorbital region within past one year . 5 . History low eyelid blepharoplasty periorbital surgery tear trough region . 6 . The subject coagulation disorder currently use anticoagulation medication 7 . History facial nerve palsy . 8 . Inability discontinue use nonsteroidal antiinflammatory drug anticoagulant prior treatment . 9 . Current participation another active clinical trial protocol 10 . Presence malar festoon 11 . Active cutaneous infection 12 . Allergy sensitivity benzocaine , lidocaine , prilocaine , tetracaine . 13 . Pregnant nursing female 14 . Other factor deem Principal Investigator would make subject unqualified participation . 15 . The subject history keloid compromise wound heal 16 . The subject know adverse reaction previous injection hyaluronic acid subcutaneously injected device</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>